Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.04
TMO's Cash to Debt is ranked lower than
51% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. TMO: 0.04 )
TMO' s 10-Year Cash to Debt Range
Min: 0.04   Max: 2.34
Current: 0.04

0.04
2.34
Equity to Asset 0.47
TMO's Equity to Asset is ranked higher than
61% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. TMO: 0.47 )
TMO' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.75
Current: 0.47

0.31
0.75
Interest Coverage 6.14
TMO's Interest Coverage is ranked higher than
57% of the 212 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.30 vs. TMO: 6.14 )
TMO' s 10-Year Interest Coverage Range
Min: 3.02   Max: 21.63
Current: 6.14

3.02
21.63
F-Score: 4
Z-Score: 1.98
M-Score: -2.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.62
TMO's Operating margin (%) is ranked higher than
83% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.19 vs. TMO: 14.62 )
TMO' s 10-Year Operating margin (%) Range
Min: 1.56   Max: 14.42
Current: 14.62

1.56
14.42
Net-margin (%) 10.31
TMO's Net-margin (%) is ranked higher than
82% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.12 vs. TMO: 10.31 )
TMO' s 10-Year Net-margin (%) Range
Min: -7.07   Max: 16.75
Current: 10.31

-7.07
16.75
ROE (%) 8.62
TMO's ROE (%) is ranked higher than
77% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.39 vs. TMO: 8.62 )
TMO' s 10-Year ROE (%) Range
Min: -8.18   Max: 15.73
Current: 8.62

-8.18
15.73
ROA (%) 4.23
TMO's ROA (%) is ranked higher than
76% of the 316 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.40 vs. TMO: 4.23 )
TMO' s 10-Year ROA (%) Range
Min: -3.29   Max: 10.39
Current: 4.23

-3.29
10.39
ROC (Joel Greenblatt) (%) 58.58
TMO's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.21 vs. TMO: 58.58 )
TMO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.07   Max: 45.97
Current: 58.58

4.07
45.97
Revenue Growth (%) 11.50
TMO's Revenue Growth (%) is ranked higher than
86% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.10 vs. TMO: 11.50 )
TMO' s 10-Year Revenue Growth (%) Range
Min: -12.9   Max: 18.7
Current: 11.5

-12.9
18.7
EBITDA Growth (%) 14.30
TMO's EBITDA Growth (%) is ranked higher than
84% of the 240 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.10 vs. TMO: 14.30 )
TMO' s 10-Year EBITDA Growth (%) Range
Min: -30   Max: 40.8
Current: 14.3

-30
40.8
EPS Growth (%) 12.80
TMO's EPS Growth (%) is ranked higher than
80% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.60 vs. TMO: 12.80 )
TMO' s 10-Year EPS Growth (%) Range
Min: -41.3   Max: 74.6
Current: 12.8

-41.3
74.6
» TMO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

TMO Guru Trades in Q4 2013

PRIMECAP Management 471,000 sh (New)
Caxton Associates 23,683 sh (New)
Jeremy Grantham 43,565 sh (+667.67%)
Leon Cooperman 825,000 sh (+34.07%)
Larry Robbins 8,535,093 sh (+5.58%)
John Rogers 846,655 sh (+1.98%)
Pioneer Investments 1,900,807 sh (+1.55%)
First Pacific Advisors 3,911,900 sh (+0.15%)
Steven Romick 3,695,000 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
Daniel Loeb Sold Out
Dodge & Cox 98,902 sh (-0.5%)
Andreas Halvorsen 10,375,656 sh (-1.85%)
Scott Black 118,570 sh (-6.1%)
John Griffin 3,425,000 sh (-7.43%)
Louis Moore Bacon 4,989 sh (-8.59%)
John Paulson 4,700,000 sh (-17.7%)
David Dreman 14,340 sh (-50.38%)
Steven Cohen 242,053 sh (-62.06%)
» More
Q1 2014

TMO Guru Trades in Q1 2014

Bill Frels 1,910 sh (New)
Ray Dalio 42,130 sh (New)
Ruane Cunniff 2,551 sh (New)
Signature Select Canadian Fund 88,800 sh (New)
Paul Tudor Jones 9,135 sh (New)
PRIMECAP Management 3,561,800 sh (+656.22%)
David Dreman 23,488 sh (+63.79%)
Larry Robbins 9,560,893 sh (+12.02%)
Leon Cooperman 847,800 sh (+2.76%)
Jean-Marie Eveillard 200 sh (unchged)
Louis Moore Bacon 4,989 sh (unchged)
Caxton Associates Sold Out
Pioneer Investments 1,850,854 sh (-2.63%)
John Paulson 4,555,000 sh (-3.09%)
Scott Black 110,672 sh (-6.66%)
Andreas Halvorsen 9,668,639 sh (-6.81%)
Steven Romick 3,315,000 sh (-10.28%)
First Pacific Advisors 3,509,100 sh (-10.3%)
Dodge & Cox 86,702 sh (-12.34%)
John Griffin 2,925,000 sh (-14.6%)
John Rogers 556,094 sh (-34.32%)
Jeremy Grantham 18,200 sh (-58.22%)
Steven Cohen 99,472 sh (-58.9%)
» More
Q2 2014

TMO Guru Trades in Q2 2014

Eric Mindich 432,000 sh (New)
Ruane Cunniff 3,101 sh (+21.56%)
Larry Robbins 10,942,193 sh (+14.45%)
PRIMECAP Management 3,962,230 sh (+11.24%)
Leon Cooperman 898,800 sh (+6.02%)
Pioneer Investments 1,923,572 sh (+3.93%)
First Pacific Advisors 3,521,200 sh (+0.34%)
Jean-Marie Eveillard 200 sh (unchged)
Steven Cohen 148,400 sh (unchged)
Steven Romick 3,315,000 sh (unchged)
Jeremy Grantham Sold Out
Ray Dalio Sold Out
Louis Moore Bacon Sold Out
John Rogers 536,928 sh (-3.45%)
Bill Frels 1,785 sh (-6.54%)
Dodge & Cox 81,002 sh (-6.57%)
John Griffin 2,715,000 sh (-7.18%)
Andreas Halvorsen 8,271,280 sh (-14.45%)
Scott Black 79,652 sh (-28.03%)
John Paulson 3,225,000 sh (-29.2%)
Paul Tudor Jones 6,390 sh (-30.05%)
David Dreman 16,420 sh (-30.09%)
» More
Q3 2014

TMO Guru Trades in Q3 2014

Steven Romick 3,315,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with TMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-06-30 Reduce -29.2%0.79%$113.59 - $122.2 $ 117.90%3225000
Andreas Halvorsen 2014-06-30 Reduce -14.45%0.71%$113.59 - $122.2 $ 117.90%8271280
Scott Black 2014-06-30 Reduce -28.03%0.39%$113.59 - $122.2 $ 117.90%79652
John Griffin 2014-06-30 Reduce -7.18%0.28%$113.59 - $122.2 $ 117.90%2715000
David Dreman 2014-06-30 Reduce -30.09%0.07%$113.59 - $122.2 $ 117.90%16420
Ray Dalio 2014-06-30 Sold Out 0.04%$113.59 - $122.2 $ 117.90%0
Ruane Cunniff 2014-06-30 Add 21.56%$113.59 - $122.2 $ 117.90%3101
John Griffin 2014-03-31 Reduce -14.6%0.57%$109.63 - $126.67 $ 117.9-1%2925000
PRIMECAP Management 2014-03-31 Add 656.22%0.42%$109.63 - $126.67 $ 117.9-1%3561800
John Rogers 2014-03-31 Reduce -34.32%0.41%$109.63 - $126.67 $ 117.9-1%556094
Andreas Halvorsen 2014-03-31 Reduce -6.81%0.37%$109.63 - $126.67 $ 117.9-1%9668639
David Dreman 2014-03-31 Add 63.79%0.09%$109.63 - $126.67 $ 117.9-1%23488
Ray Dalio 2014-03-31 New Buy0.04%$109.63 - $126.67 $ 117.9-1%42130
Ruane Cunniff 2014-03-31 New Buy$109.63 - $126.67 $ 117.9-1%2551
Daniel Loeb 2013-12-31 Sold Out 3.6%$89.93 - $110.67 $ 117.919%0
John Paulson 2013-12-31 Reduce -17.7%0.6%$89.93 - $110.67 $ 117.919%4700000
Leon Cooperman 2013-12-31 Add 34.07%0.33%$89.93 - $110.67 $ 117.919%825000
John Griffin 2013-12-31 Reduce -7.43%0.3%$89.93 - $110.67 $ 117.919%3425000
David Dreman 2013-12-31 Reduce -50.38%0.12%$89.93 - $110.67 $ 117.919%14340
PRIMECAP Management 2013-12-31 New Buy0.06%$89.93 - $110.67 $ 117.919%471000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Thermo Fisher Scientific Inc

John Rogers Comments on Thermo Fisher Scientific Inc. - May 07, 2014

In addition, scientific research specialist Thermo Fisher Scientific Inc. (TMO) returned +8.12% after a very solid earnings report. Its revenue was $3.5 billion, up 6% over the previous period, and its earnings per share was $1.43, significantly above the $1.37 cons ensus estimate. Its forecast for 2014 was even more positive : full-year revenue guidance was in the $16 billion-plus ra nge, smashing the $13 billion consensus estimate, and the low end of its EPS guidance was more than $0.40 higher than Wall Street's best guess. Our strategy with Thermo Fisher has been to look beyond the gloom and doom that has cast a dark cloud over the whole sector to see the potential for a bright future.



From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund first quarter 2014 letter.

Check out John Rogers latest stock trades

Top Ranked Articles about Thermo Fisher Scientific Inc

John Rogers Comments on Thermo Fisher Scientific Inc.
In addition, scientific research specialist Thermo Fisher Scientific Inc. (TMO) returned +8.12% after a very solid earnings report. Its revenue was $3.5 billion, up 6% over the previous period, and its earnings per share was $1.43, significantly above the $1.37 cons ensus estimate. Its forecast for 2014 was even more positive : full-year revenue guidance was in the $16 billion-plus ra nge, smashing the $13 billion consensus estimate, and the low end of its EPS guidance was more than $0.40 higher than Wall Street's best guess. Our strategy with Thermo Fisher has been to look beyond the gloom and doom that has cast a dark cloud over the whole sector to see the potential for a bright future. Read more...
Steven Romick's Top Five Highlight Technology Sector
Steven Romick is the portfolio manager of First Pacific Advisors Crescent Fund. The fund’s investment objective and strategy reports that they “seek to generate equity-like returns over the long-term, take less risk than the market and avoid permanent impairment of capital.” Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 30.80
TMO's P/E(ttm) is ranked higher than
74% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.70 vs. TMO: 30.80 )
TMO' s 10-Year P/E(ttm) Range
Min: 11.11   Max: 55.16
Current: 30.8

11.11
55.16
P/B 2.28
TMO's P/B is ranked higher than
74% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.99 vs. TMO: 2.28 )
TMO' s 10-Year P/B Range
Min: 0.5   Max: 2.67
Current: 2.28

0.5
2.67
P/S 3.06
TMO's P/S is ranked higher than
65% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. TMO: 3.06 )
TMO' s 10-Year P/S Range
Min: 1.24   Max: 3.48
Current: 3.06

1.24
3.48
PFCF 23.87
TMO's PFCF is ranked higher than
84% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 84.15 vs. TMO: 23.87 )
TMO' s 10-Year PFCF Range
Min: 10.22   Max: 32.28
Current: 23.87

10.22
32.28
EV-to-EBIT 29.97
TMO's EV-to-EBIT is ranked higher than
74% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.53 vs. TMO: 29.97 )
TMO' s 10-Year EV-to-EBIT Range
Min: 11.2   Max: 73.5
Current: 29.97

11.2
73.5
PEG 2.14
TMO's PEG is ranked higher than
92% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. TMO: 2.14 )
TMO' s 10-Year PEG Range
Min: 0.56   Max: 11.39
Current: 2.14

0.56
11.39
Shiller P/E 37.28
TMO's Shiller P/E is ranked higher than
76% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 224.47 vs. TMO: 37.28 )
TMO' s 10-Year Shiller P/E Range
Min: 16.89   Max: 73.81
Current: 37.28

16.89
73.81
Current Ratio 0.95
TMO's Current Ratio is ranked higher than
50% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.74 vs. TMO: 0.95 )
TMO' s 10-Year Current Ratio Range
Min: 0.95   Max: 3.83
Current: 0.95

0.95
3.83
Quick Ratio 0.64
TMO's Quick Ratio is ranked higher than
50% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.82 vs. TMO: 0.64 )
TMO' s 10-Year Quick Ratio Range
Min: 0.64   Max: 3.4
Current: 0.64

0.64
3.4

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.51
TMO's Dividend Yield is ranked lower than
82% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. TMO: 0.51 )
TMO' s 10-Year Dividend Yield Range
Min: 0.22   Max: 0.86
Current: 0.51

0.22
0.86
Dividend Payout 0.16
TMO's Dividend Payout is ranked higher than
99% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. TMO: 0.16 )
TMO' s 10-Year Dividend Payout Range
Min: 0.11   Max: 0.22
Current: 0.16

0.11
0.22
Yield on cost (5-Year) 0.50
TMO's Yield on cost (5-Year) is ranked lower than
79% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. TMO: 0.50 )
TMO' s 10-Year Yield on cost (5-Year) Range
Min: 0.22   Max: 0.86
Current: 0.5

0.22
0.86
Share Buyback Rate 3.70
TMO's Share Buyback Rate is ranked higher than
95% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. TMO: 3.70 )
TMO' s 10-Year Share Buyback Rate Range
Min: 4.6   Max: -38.3
Current: 3.7

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.22
TMO's Price/DCF (Projected) is ranked higher than
87% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. TMO: 1.22 )
TMO' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 43.45
Current: 1.22

0.6
43.45
Price/Median PS Value 1.41
TMO's Price/Median PS Value is ranked higher than
52% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. TMO: 1.41 )
TMO' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 1.51
Current: 1.41

0.39
1.51
Price/Peter Lynch Fair Value 1.95
TMO's Price/Peter Lynch Fair Value is ranked higher than
90% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. TMO: 1.95 )
TMO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.59   Max: 3.28
Current: 1.95

0.59
3.28
Earnings Yield (Greenblatt) 3.30
TMO's Earnings Yield (Greenblatt) is ranked higher than
57% of the 231 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. TMO: 3.30 )
TMO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 8.9
Current: 3.3

1.4
8.9
Forward Rate of Return (Yacktman) 18.39
TMO's Forward Rate of Return (Yacktman) is ranked higher than
93% of the 274 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.38 vs. TMO: 18.39 )
TMO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -18.8   Max: 34
Current: 18.39

-18.8
34

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, COO, ISRG » details
Traded in other countries:TN8.Germany, TMO.Mexico
Thermo Fisher Scientific Inc., is a Delaware corporation and was incorporated in 1956. The Company enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. In November 2006, Thermo Electron Corporation merged with Fisher Scientific International Inc. to create Thermo Fisher. The Company completed its initial public offering in 1967. It serves more than 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial quality and process control settings. The Company's continuing operations fall into three business segments: Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services. Analytical Technologies segment provides offerings of instruments, reagents, consumables, software and services that are used for applications in the laboratory, on the production line and in the field. These products are used by customers in all four of the company's key end markets: healthcare and diagnostics; pharmaceutical and biotechnology; academic and government; and industrial and applied. This segment includes four primary businesses - Chromatography and Mass Spectrometry, Chemical Analysis, Environmental and Process Instruments, and Biosciences. Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. Its chemical analysis products fall into three main categories: materials and minerals; molecular spectroscopy; and portable analytical instruments. Customers use these products to quickly and accurately analyze the composition of materials in small samples to optimize workflows in academic, life sciences, pharmaceutical, and industrial applications. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Services segment provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products and an extensive service offering. These products and services are used by customers in pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory. The Company markets and sells its products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors and various catalogs. It encounters aggressive and able competition in virtually all of the markets it serves. It is subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the United States and other countries.
» More Articles for TMO

Headlines

Articles On GuruFocus.com
Glenview's Larry Robbins Adds to Stake in Watchmaker Fossil Sep 15 2014 
John Rogers Comments on Thermo Fisher Scientific Inc. May 07 2014 
John Rogers' Ariel Appreciation Fund First Quarter 2014 Commentary Apr 30 2014 
Steven Romick's Top Five Highlight Technology Sector Apr 16 2014 
Different Opinions on Bio-Rad Laboratories Apr 03 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
Steven Romick’s Top Five Q4 Holdings Jan 14 2014 
Daniel Loeb, Third Point Selling Update - TIF, DIS, YHOO, WCC, TMO Nov 15 2013 
John Rogers' Ariel Fund and Ariel Appreciate Fund Portfolio Manager Letter Oct 28 2013 


More From Other Websites
Final Glance: Health Care Equipment companies Oct 24 2014
Final Glance: Health Care Equipment companies Oct 24 2014
Midday Glance: Health Care Equipment companies Oct 24 2014
Midday Glance: Health Care Equipment companies Oct 24 2014
Early Glance: Health Care Equipment companies Oct 24 2014
Early Glance: Health Care Equipment companies Oct 24 2014
Thermo Fisher Scientific (TMO) Earnings Report: Q3 2014 Conference Call Transcript Oct 23 2014
Biogen, Thermo Reports Disappoint; Abbott Accelerates Oct 22 2014
Thermo Fisher Tops Earnings, Cuts View on Currency Woes Oct 22 2014
Thermo Fisher tops 3Q forecasts, adjusts outlook Oct 22 2014
Thermo Fisher tops 3Q forecasts, adjusts outlook Oct 22 2014
Thermo Fisher profit jumps but revenue disappoints, shares drop Oct 22 2014
Thermo Fisher Scientific (TMO) Showing Unusual Social Activity Today Oct 22 2014
Why Thermo Fisher Scientific (TMO) Stock Is Declining Today Oct 22 2014
THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Oct 22 2014
Q3 2014 Thermo Fisher Scientific Inc Earnings Release - Before Market Open Oct 22 2014
Thermo Fisher profit jumps as Life Tech buyout pays off Oct 22 2014
Thermo Fisher Scientific Reports Third Quarter 2014 Results Oct 22 2014
Is Thermo Fisher (TMO) Poised to Surprise Q3 Earnings? Oct 20 2014
Stock Futures Sweep Lower; Netflix, Baker Hughes Dive Oct 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK